126 related articles for article (PubMed ID: 33448139)
21. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
Haltia UM; Hallamaa M; Tapper J; Hynninen J; Alfthan H; Kalra B; Ritvos O; Heikinheimo M; Unkila-Kallio L; Perheentupa A; Färkkilä A
Gynecol Oncol; 2017 Jan; 144(1):83-89. PubMed ID: 27871721
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of new biomarkers in stage III and IV endometriosis.
Kovalak EE; Karacan T; Zengi O; Karabay Akgül Ö; Özyürek ŞE; Güraslan H
Gynecol Endocrinol; 2023 Dec; 39(1):2217290. PubMed ID: 37236244
[TBL] [Abstract][Full Text] [Related]
23. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses.
Tanir HM; Ozalp S; Yalcin OT; Colak O; Akcay A; Senses T
Eur J Gynaecol Oncol; 2003; 24(3-4):271-4. PubMed ID: 12807238
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Azzam AZ; Hashad DI; Kamel NA
Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
[TBL] [Abstract][Full Text] [Related]
25. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
26. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
27. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
28. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
29. IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas.
Crispim PCA; Jammal MP; Antão PKA; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Am J Reprod Immunol; 2020 Dec; 84(6):e13309. PubMed ID: 32698242
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
31. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
Gorelik E; Landsittel DP; Marrangoni AM; Modugno F; Velikokhatnaya L; Winans MT; Bigbee WL; Herberman RB; Lokshin AE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):981-7. PubMed ID: 15824174
[TBL] [Abstract][Full Text] [Related]
32. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
34. Accurate diagnosis of endometriosis using serum microRNAs.
Moustafa S; Burn M; Mamillapalli R; Nematian S; Flores V; Taylor HS
Am J Obstet Gynecol; 2020 Oct; 223(4):557.e1-557.e11. PubMed ID: 32165186
[TBL] [Abstract][Full Text] [Related]
35. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Wang J; Zhu M; Zhou X; Wang T; Zhang J
J BUON; 2020; 25(5):2287-2292. PubMed ID: 33277847
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
37. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
38. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
39. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
40. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis.
Othman Eel-D; Hornung D; Salem HT; Khalifa EA; El-Metwally TH; Al-Hendy A
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):240-6. PubMed ID: 17582674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
